Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 92 Defects/Health Damages Reported for Kymriah in October-March
July 13, 2022
- All 10 Pharma-Backed Candidates Grab Upper House Seats
July 12, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- After Abe’s Death, Pharma and Medical Circles Fret Shift to Austerity and Tougher Drug Pricing
July 11, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
July 11, 2022
- Label Revision Ordered for Novavax Jab to Add Myocarditis Risks
July 11, 2022
- Drug Makers Can Now Access MID-NET from Their Own Offices
July 11, 2022
- Japan to Discuss Fourth COVID Shot for Below Age 60: Govt Official
July 8, 2022
- Panel Designates COVID, Monkeypox and Other Priority Infectious Diseases for SCARDA Funding
July 8, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
- MHLW Preparing Inspection Manual after GMP Issues, Draft Due Out by March-End
July 5, 2022
- 8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem
July 4, 2022
- 5 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 4, 2022
- Online NDA Submission Starts in Japan: MHLW/PMDA
July 4, 2022
- VLP and Shionogi 1st to Be Selected for SCARDA Vaccine Funding Program
July 4, 2022
- FDA Philippines to Expedite Review Process of Japan-Approved Drugs
July 1, 2022
- AMED Employees’ Annual Pay Averaged 9.3 Million Yen in FY2021
July 1, 2022
- Ryukaikon to Assess Situation of Products Distributed by Single Wholesalers
July 1, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- Survey Finds 11.7% of Wholesaler Transactions Negotiated through Proxies: MHLW
June 30, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…